GLP-1 receptor agonists (GLP-1RAs) are drugs originally developed for diabetes and obesity. In experimental models of pulmonary arterial hypertension GLP-1RA’s administration attenuates the severity of pulmonary hypertension. Additional studies highlight their ability to protect against lung fibrosis and preserve endothelial function. No clinical trials have yet tested GLP-1RAs specifically in pulmonary arterial hypertension, though observational data in heart failure patients hint at cardiopulmonary benefits. The authors argue GLP-1RAs are a promising candidate worth rigorous clinical testing as a potential disease-modifying therapy.
Read more at this link on the European Respiratory Journal Open Research
Citation
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension, Benoit Aguado, Thomas Lacoste-Palasset, Grégoire Ruffenach, ERJ Open Research 2026 12(3): 01479-2025; DOI: https://doi.org/10.1183/23120541.01479-2025